Skip to content

The protection of left ventricular function during right ventricular pacing.

PROTECT-PACE study: To assess the protection of left ventricular function during right ventricular pacing in patients diagnosed with complete heart block.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12607000479404
Enrollment
238
Registered
2007-09-21
Start date
2007-08-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

For many years the standard approach to lead placement has been the right ventricular apex (RVA). However, early evidence suggests that right ventricular high septum (RVHS) pacing may be more beneficial compared to RVA pacing. Patients with complete heart block requiring more than 90% ventricular pacing will be randomised into two groups; RVA vs RVHS pacing. The two pacing modalities will be compared to assess left ventricular function as measured by the left ventricular ejection fraction.

Interventions

Implant of pacemaker and lead system. Results after a follow-up period of 24 months will be compared between right ventricular apex (RVA) vs right ventricular high septum (RVHS) lead placement. At the end of the study the treatment continues. Right ventricular apex: Area at the base of the right ventricle in the heart. Right ventricular high septum: Area near the top of the right ventricle closer to the middle of the heart.

Sponsors

Medtronic Australasia
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to -2147483648 No limit
Healthy volunteers
No

Inclusion criteria

Patients diagnosed with high-grade A-V block scheduled to undergo pacemaker implantation.

Exclusion criteria

Patient with intermittent AV block or scheduled for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026